Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.

Cell cycle (Georgetown, Tex.) - 1 Nov 2011

Carr-Wilkinson Jane, Griffiths Rebecca, Elston Rebecca, Gamble Laura D, Goranov Bojidar, Redfern Christopher P F, Lunec John, Tweddle Deborah A

Abstract excerpt

BACKGROUND: MYCN oncogene amplification occurs in 20-25% of neuroblastoma and is associated with a poor prognosis. We previously reported that MYCN amplified (MNA) p53 wild-type neuroblastoma cell lines failed to G1 arrest in response to irradiation, but this could not be attributed to MYCN alone. HYPOTHESIS: Genes co-amplified with MYCN and/or the predominant cell type, neuronal (N) or substrate adherent (S)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Damage
Share to DNA Repair

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to N-Myc Proto-Oncogene Protein

Share to Neuroblastoma

Share to Oncogene Proteins

Share to RNA Interference

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 22052359
DOI: 10.4161/cc.10.21.17973

Genes

MYCN
MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Outcome of the p53-mediated DNA damage response in neuroblastoma is determined by morphological subtype and MYCN expression.PMID 22052359Read ↗

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastomaSemantic proximity Read ↗

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.Semantic proximity Read ↗

Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroupSemantic proximity Read ↗

Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk NeuroblastomaSemantic proximity Read ↗

DNA‐damaging drug‐induced apoptosis sensitized by <i>N‐myc</i> in neuroblastoma cellsSemantic proximity Read ↗

The p53 regulatory gene <i>MDM2</i> is a direct transcriptional target of MYCN in neuroblastomaSemantic proximity Read ↗

Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.Semantic proximity Read ↗

Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiationSemantic proximity Read ↗

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastomaSemantic proximity Read ↗

Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor CellsSemantic proximity Read ↗

MYCN Amplification Is Associated with Reduced Expression of Genes Encoding γ-Secretase Complex and NOTCH Signaling Components in NeuroblastomaSemantic proximity Read ↗

CDK4 inhibition restores G₁-S arrest in<i><i>MYCN</i>-</i>amplified neuroblastoma cells in the context of doxorubicin-induced DNA damageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.